MX2021007475A - Compuestos de 3-((3-aminofenil)amino)piperidina-2,6-diona sustituida, composiciones de estos y metodos de tratamiento con estos. - Google Patents
Compuestos de 3-((3-aminofenil)amino)piperidina-2,6-diona sustituida, composiciones de estos y metodos de tratamiento con estos.Info
- Publication number
- MX2021007475A MX2021007475A MX2021007475A MX2021007475A MX2021007475A MX 2021007475 A MX2021007475 A MX 2021007475A MX 2021007475 A MX2021007475 A MX 2021007475A MX 2021007475 A MX2021007475 A MX 2021007475A MX 2021007475 A MX2021007475 A MX 2021007475A
- Authority
- MX
- Mexico
- Prior art keywords
- compositions
- methods
- piperidine
- compounds
- aminophenyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/94—Oxygen atom, e.g. piperidine N-oxide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/98—Nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/30—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/86—Oxygen and sulfur atoms, e.g. thiohydantoin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862782281P | 2018-12-19 | 2018-12-19 | |
| US201962879927P | 2019-07-29 | 2019-07-29 | |
| PCT/US2019/067090 WO2020132016A1 (en) | 2018-12-19 | 2019-12-18 | Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021007475A true MX2021007475A (es) | 2021-08-05 |
Family
ID=71099150
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021007475A MX2021007475A (es) | 2018-12-19 | 2019-12-18 | Compuestos de 3-((3-aminofenil)amino)piperidina-2,6-diona sustituida, composiciones de estos y metodos de tratamiento con estos. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11325889B2 (https=) |
| EP (1) | EP3897635A4 (https=) |
| JP (1) | JP7492962B2 (https=) |
| KR (1) | KR102864064B1 (https=) |
| CN (1) | CN113473987B (https=) |
| AU (1) | AU2019404022A1 (https=) |
| BR (1) | BR112021012186A2 (https=) |
| CA (1) | CA3124101A1 (https=) |
| IL (1) | IL284187A (https=) |
| MX (1) | MX2021007475A (https=) |
| SG (1) | SG11202106506WA (https=) |
| TW (1) | TW202039434A (https=) |
| WO (1) | WO2020132016A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113453681B (zh) | 2018-12-19 | 2024-10-11 | 细胞基因公司 | 经取代的3-((3-氨基苯基)氨基)哌啶-2，6-二酮化合物、其组合物及使用它们的治疗方法 |
| AU2020405129A1 (en) | 2019-12-19 | 2022-06-23 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
| CR20220630A (es) | 2020-05-09 | 2023-01-23 | Arvinas Operations Inc | Métodos para fabricar un compuesto bifuncional, formas ultrapuras del compuesto bifuncional y formas de dosificación que comprenden el mismo |
| JP7778095B2 (ja) | 2020-06-24 | 2025-12-01 | セルジーン コーポレーション | セレブロン結合化合物、その組成物及びそれによる治療方法 |
| KR20230027214A (ko) | 2020-06-24 | 2023-02-27 | 셀진 코포레이션 | 세레블론 결합 화합물, 이의 조성물, 및 이에 의한 치료 방법 |
| KR20230027066A (ko) | 2020-06-24 | 2023-02-27 | 셀진 코포레이션 | 세레블론 결합 화합물, 이의 조성물, 및 이에 의한 치료 방법 |
| EP4438603A4 (en) | 2021-11-25 | 2025-06-11 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | CHIMERIC COMPOUND FOR TARGETED DEGRADATION OF ANDROGEN RECEPTOR PROTEIN, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF |
| TW202535392A (zh) | 2023-12-08 | 2025-09-16 | 美商亞文納營運公司 | 使用雄性素受體降解劑治療脊髓延髓性肌肉萎縮 |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4302485A1 (de) * | 1993-01-29 | 1994-08-04 | Merck Patent Gmbh | Piperazinderivate |
| FR2768728B1 (fr) | 1997-09-19 | 1999-12-03 | Rhodia Chimie Sa | Procede d'acylation d'un compose aromatique |
| FR2768729A1 (fr) | 1997-09-19 | 1999-03-26 | Rhodia Chimie Sa | Procede d'acylation d'un compose aromatique et complexes catalytiques |
| US7629360B2 (en) | 1999-05-07 | 2009-12-08 | Celgene Corporation | Methods for the treatment of cachexia and graft v. host disease |
| US8470829B2 (en) * | 2004-09-09 | 2013-06-25 | Chugai Seiyaku Kabushiki Kaisha | Imidazolidine derivative and use thereof |
| WO2007073432A2 (en) | 2005-10-11 | 2007-06-28 | Chemocentryx, Inc. | Piperidine derivatives and methods of use |
| US20080064876A1 (en) * | 2006-05-16 | 2008-03-13 | Muller George W | Process for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione |
| AU2010273220B2 (en) | 2009-07-13 | 2015-10-15 | President And Fellows Of Harvard College | Bifunctional stapled polypeptides and uses thereof |
| RU2434851C1 (ru) | 2010-07-22 | 2011-11-27 | Александр Васильевич Иващенко | Циклические n, n'-диарилтиомочевины или n, n'-диарилмочевины - антагонисты андрогенных рецепторов, противораковое средство, способ получения и применения |
| US8765978B2 (en) | 2010-12-16 | 2014-07-01 | Transitions Optical, Inc. | Method of making indeno-fused naphthol materials |
| EP2683694B1 (en) * | 2011-03-10 | 2016-04-27 | Suzhou Kintor Pharmaceuticals, Inc. | Androgen receptor antagonists and uses thereof |
| US20140112922A1 (en) | 2011-03-28 | 2014-04-24 | Cornell University | Targeted protein silencing using chimeras between antibodies and ubiquitination enzymes |
| KR102668696B1 (ko) | 2012-01-12 | 2024-05-29 | 예일 유니버시티 | E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법 |
| WO2014036897A1 (zh) * | 2012-09-04 | 2014-03-13 | 上海恒瑞医药有限公司 | 咪唑啉类衍生物、其制备方法及其在医药上的应用 |
| USRE48175E1 (en) | 2012-10-19 | 2020-08-25 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged small molecules as inducers of protein degradation |
| RU2683788C2 (ru) | 2013-01-31 | 2019-04-02 | Вертекс Фармасьютикалз Инкорпорейтед | Амиды хинолина и хиназолина, полезные в качестве модуляторов натриевых каналов |
| RU2738833C9 (ru) | 2014-04-14 | 2022-02-28 | Арвинас, Оперэйшнз, Инк. | Имидные модуляторы протеолиза и способы их применения |
| US20160058872A1 (en) | 2014-04-14 | 2016-03-03 | Arvinas, Inc. | Imide-based modulators of proteolysis and associated methods of use |
| RU2557235C1 (ru) | 2014-07-08 | 2015-07-20 | Александр Васильевич Иващенко | Замещенные 2-тиоксо-имидазолидин-4-оны и их спироаналоги, противораковый активный компонент, фармацевтическая композиция, лекарственный препарат, способ лечения рака простаты |
| WO2016105518A1 (en) | 2014-12-23 | 2016-06-30 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| US9694084B2 (en) | 2014-12-23 | 2017-07-04 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| JP6817962B2 (ja) | 2015-01-20 | 2021-01-20 | アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． | ターゲティングされたアンドロゲン受容体分解のための化合物および方法 |
| EP3270917A4 (en) | 2015-03-18 | 2018-08-08 | Arvinas, Inc. | Compounds and methods for the enhanced degradation of targeted proteins |
| GB201506871D0 (en) | 2015-04-22 | 2015-06-03 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| EP3319944A4 (en) | 2015-07-10 | 2019-04-24 | Arvinas, Inc. | MDM2-BASED MODULATORS OF PROTEOLYSIS AND RELATED USE METHODS |
| US10772962B2 (en) | 2015-08-19 | 2020-09-15 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of bromodomain-containing proteins |
| TWI726969B (zh) | 2016-01-11 | 2021-05-11 | 比利時商健生藥品公司 | 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物 |
| CN109641874A (zh) | 2016-05-10 | 2019-04-16 | C4医药公司 | 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体 |
| CN110167556A (zh) | 2016-07-08 | 2019-08-23 | 詹森药业有限公司 | 用于治疗癌症的硫代乙内酰脲雄性激素受体拮抗剂 |
| TWI739888B (zh) | 2016-10-07 | 2021-09-21 | 美商陶氏農業科學公司 | 農藥組合物及方法 |
| CN110506039A (zh) | 2016-10-11 | 2019-11-26 | 阿尔维纳斯股份有限公司 | 用于雄激素受体靶向降解的化合物和方法 |
| US10925868B2 (en) | 2016-11-10 | 2021-02-23 | Dana-Farber Cancer Institute, Inc. | Degradation of protein kinases by conjugation of protein kinase inhibitors with E3 ligase ligand and methods of use |
| WO2018098280A1 (en) | 2016-11-22 | 2018-05-31 | Dana-Farber Cancer Institute, Inc. | Degradation of protein kinases by conjugation of protein kinase inhibitors with e3 ligase ligand and methods of use |
| AU2017378943B2 (en) | 2016-12-19 | 2020-06-18 | Abbisko Therapeutics Co., Ltd. | FGFR4 inhibitor, preparation method therefor and pharmaceutical use thereof |
| IL312367A (en) | 2017-01-31 | 2024-06-01 | Arvinas Operations Inc | Cereblon ligands and bifunctional compounds comprising the same |
| CN110769822A (zh) | 2017-06-20 | 2020-02-07 | C4医药公司 | 用于蛋白降解的n/o-连接的降解决定子和降解决定子体 |
| CN109422725A (zh) | 2017-09-04 | 2019-03-05 | 北京美倍他药物研究有限公司 | 前列腺癌治疗药物 |
| ES2959954T3 (es) | 2017-11-28 | 2024-02-29 | Aarti Pharmalabs Ltd | Proceso para la preparación de enzalutamida utilizando un nuevo intermedio |
| EP3720281A4 (en) | 2017-12-05 | 2021-05-26 | Dow Agrosciences LLC | PESTICIDE COMPOSITIONS AND PROCEDURES |
| CN114835729B (zh) | 2018-05-30 | 2024-05-31 | 江苏豪森药业集团有限公司 | 含三并环类衍生物抑制剂、其制备方法和应用 |
| CN109651256A (zh) | 2018-11-20 | 2019-04-19 | 上海健康医学院 | 一种式（viii）的恩杂鲁胺的制备方法 |
| CN113453681B (zh) | 2018-12-19 | 2024-10-11 | 细胞基因公司 | 经取代的3-((3-氨基苯基)氨基)哌啶-2，6-二酮化合物、其组合物及使用它们的治疗方法 |
-
2019
- 2019-12-18 CN CN201980092186.9A patent/CN113473987B/zh active Active
- 2019-12-18 US US16/719,217 patent/US11325889B2/en active Active
- 2019-12-18 BR BR112021012186-2A patent/BR112021012186A2/pt not_active Application Discontinuation
- 2019-12-18 WO PCT/US2019/067090 patent/WO2020132016A1/en not_active Ceased
- 2019-12-18 JP JP2021535546A patent/JP7492962B2/ja active Active
- 2019-12-18 EP EP19899239.8A patent/EP3897635A4/en active Pending
- 2019-12-18 KR KR1020217022417A patent/KR102864064B1/ko active Active
- 2019-12-18 AU AU2019404022A patent/AU2019404022A1/en not_active Abandoned
- 2019-12-18 CA CA3124101A patent/CA3124101A1/en active Pending
- 2019-12-18 TW TW108146432A patent/TW202039434A/zh unknown
- 2019-12-18 MX MX2021007475A patent/MX2021007475A/es unknown
- 2019-12-18 SG SG11202106506WA patent/SG11202106506WA/en unknown
-
2021
- 2021-06-20 IL IL284187A patent/IL284187A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3124101A1 (en) | 2020-06-25 |
| TW202039434A (zh) | 2020-11-01 |
| EP3897635A4 (en) | 2022-08-31 |
| JP2022514347A (ja) | 2022-02-10 |
| AU2019404022A1 (en) | 2021-07-08 |
| US20200199074A1 (en) | 2020-06-25 |
| IL284187A (en) | 2021-08-31 |
| WO2020132016A1 (en) | 2020-06-25 |
| CN113473987B (zh) | 2024-09-03 |
| SG11202106506WA (en) | 2021-07-29 |
| US11325889B2 (en) | 2022-05-10 |
| JP7492962B2 (ja) | 2024-05-30 |
| KR102864064B1 (ko) | 2025-09-24 |
| CN113473987A (zh) | 2021-10-01 |
| KR20210118828A (ko) | 2021-10-01 |
| BR112021012186A2 (pt) | 2021-08-31 |
| EP3897635A1 (en) | 2021-10-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY205718A (en) | Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith | |
| MX2021007475A (es) | Compuestos de 3-((3-aminofenil)amino)piperidina-2,6-diona sustituida, composiciones de estos y metodos de tratamiento con estos. | |
| SA522441857B1 (ar) | مركبات ربط سيريبلون، توليفات منها، وطرق للمعالجة باستخدامها | |
| MX2021014350A (es) | Compuestos de 1-oxo-isoindolin-5-carboxamida sustituida, composiciones de los mismos y metodos de tratamiento con los mismos. | |
| PH12021551167A1 (en) | New heterocyclic compounds | |
| PH12021500013A1 (en) | New heterocyclic compounds as monoacylgylcerol lipase inhibitors | |
| MX2025003987A (es) | Antagonistas de cinasa progenitora hematopoyetica 1 (hpk1) y sus usos | |
| MY206796A (en) | Substituted 4-aminoisoindoline-1,3-dione compounds and their use for treating lymphoma | |
| PH12021550505A1 (en) | Substituted thiohydantoin derivatives as androgen receptor antagonists | |
| MX377277B (es) | Derivados de fenoximetilo. | |
| MX2021014531A (es) | Compuestos de aminopurina sustituida, composiciones del mismo, y metodos de tratamiento con los mismos. | |
| MY188114A (en) | Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection | |
| EA201890256A1 (ru) | 2-амино-3-фтор-3-(фторметил)-6-метил-6-фенил-3,4,5,6-тетрагидропиридины в качестве ингибиторов bace1 | |
| EA202190464A1 (ru) | Замещенные бензимидазолы в качестве ингибиторов pad4 | |
| MX2020006290A (es) | Dinucleotidos ciclicos como agonistas de sting. | |
| PH12021553249A1 (en) | New heterocyclic compounds | |
| PH12019502277A1 (en) | Crystalline forms of (s)-afoxolaner | |
| EA202190272A1 (ru) | Дополнительно замещенные производные триазолохиноксалина | |
| DK1480627T3 (da) | Fremgangsmåder til mindskelse af angiogenese | |
| EA202190271A1 (ru) | Замещенные триазолохиноксалиновые производные | |
| MX2021000625A (es) | Dinucleotidos ciclicos como agonistas de sting. | |
| MX2023009059A (es) | Antagonistas de gpr84 y usos de estos. | |
| MX2023014984A (es) | Anticuerpos anti-csp. | |
| SA522432781B1 (ar) | مركب مضاد pd-l1 | |
| EA202192237A1 (ru) | Кристаллические формы ингибитора jak2 |